Matthew Vander Heiden is elected as a member of the National Academy of Medicine
Matthew Vander Heiden, Director of the Koch Institute for Integrative Cancer Research at MIT, was recently elected as a member of the National Academy of Medicine.
Matthew Vander Heiden is a prominent figure in cancer research, currently serving as the Director of the Koch Institute for Integrative Cancer Research at MIT and the Lester Wolfe (1919) Professor of Molecular Biology. He is also an instructor in medicine at the Dana-Farber Cancer Institute and Harvard Medical School.
Education and Training
Vander Heiden earned both his PhD and MD from the University of Chicago in 2000 and 2002, respectively. His academic journey included a residency in internal medicine at Brigham and Women’s Hospital, followed by a fellowship in hematology-oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital. He later completed a postdoctoral fellowship in Lewis Cantley’s lab at Harvard Medical School.
Research Focus
Vander Heiden’s research primarily investigates the biochemical pathways that enable cancer cells to meet their metabolic needs, particularly in relation to pancreatic cancer.
His lab explores how metabolic changes influence cancer progression and response to therapies. This includes studying how pancreatic cancer cells adapt their metabolism for tumor growth and how these changes affect overall body metabolism, leading to conditions such as weight loss and tissue wasting.
Career Achievements
Since joining MIT’s faculty in 2010, Vander Heiden has received numerous accolades, including:
- Howard Hughes Medical Institute Faculty Scholar (2016)
- SU2C Innovative Research Grant Recipient (2016)
- Burroughs Wellcome Fund Career Award for Medical Scientists (2009)
- He was appointed Director of the Koch Institute in 2021 after ten years of significant contributions to cancer research.
Collaborative Efforts
Vander Heiden is involved with various scientific advisory boards, including those for the Yale Cancer Center and Agios Pharmaceuticals. His interdisciplinary approach integrates insights from biology, engineering, and computational sciences to advance cancer research.
Interviews
Meet the new MIT Koch Institute director, Matthew Vander Heiden
Inside the Lab: Matthew Vander Heiden, M.D., Ph.D.
Meet an IRG Recipient: Matthew Vander Heiden
Matthew G. Vander Heiden, MD, PhD, a Damon Runyon Scientist
Toni Choueiri, Director of the Lank Center for GU Oncology at Dana-Farber Cancer Institute, shared a post on X, congratulating him:
“Our Dana-Farber Cancer Institute andKoch Institute at MIT Dr. Matt Vander Heiden elected to National Academy of Medicine. Matt also sees patients Dana-Farber Lank Center for Genitourinary Oncology while leading the Koch Institute at MIT.
Huge Congratulations Matt!”
National Academy of Medicine Elects 100 New Members
About the National Academy of Medicine
The National Academy of Medicine (NAM), previously known as the Institute of Medicine (IoM) until its rebranding in 2015, is a prominent nonprofit, non-governmental organization in the United States. It operates as one of the three academies under the umbrella of the National Academies of Sciences, Engineering, and Medicine.
Established in 1970, the NAM was created to provide expert advice on health, medical care, and biomedical science issues. The organization is composed of a diverse group of members elected for their distinguished contributions to medicine and health. Currently, Dr. Victor J. Dzau serves as its president, having held this position since July 2014.
For more posts like this, visit oncodaily.com.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023